COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #127
Source   PDF   Share   Tweet
See all 182 studies
9/14
Positive
Late treatment study
Lauriola et al., Clinical and Translational Science, doi:10.1111/cts.12860 (Peer Reviewed)
Effect of combination therapy of hydroxych loroquine and azithromycin on mortality in COVID‐19 patients
Retrospective 377 patients, 73% reduction in mortality with HC Q+AZ, adjusted hazard ratio HR 0.27 [0.17-0.41]. Mean age 71.8. No serious adverse events. Subject to incomplete adjustment for confounders.
death, ↓73.5%, p<0.001
Source   PDF   Share   Tweet
See all 182 studies
Please send us corrections, updates, or comments.
Submit